TYK2-JAK1

Overview

TYK2-JAK1 refers to a dual-target protein axis involving tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), two closely related members of the Janus kinase family that mediate cytokine receptor signaling. In biomedical research and drug development, this target is most often discussed in the context of small-molecule inhibitors designed to modulate inflammatory and immune pathways by suppressing downstream signaling through STAT proteins and related networks.

Because TYK2 and JAK1 participate in overlapping cytokine-driven pathways, they are relevant to diseases characterized by immune dysregulation, including psoriasis, dermatomyositis, and other inflammatory disorders. Pharmacologic inhibition of this axis is intended to reduce pathological cytokine signaling while preserving enough immune function for clinical tolerability. Recent studies have also linked JAK-family signaling to broader pathway interactions such as mTORC1/2 and JAK2/signal transducer and activator of transcription 3 (STAT3) signaling, underscoring the network-level effects of targeting TYK2-JAK1 in inflammatory and proliferative disease settings.

Recent Publications Focus

Recent research highlights TYK2-JAK1 as a versatile therapeutic target with applications across inflammatory, autoimmune, regenerative, and malignant diseases. In dermatomyositis, brepocitinib, a first-in-class, oral, selective TYK2-JAK1 inhibitor that blocks cytokine signaling implicated in the disease, has been evaluated in a phase 3 trial 41910335Mar. In psoriasis, TYK2 inhibition demonstrates dual therapeutic potential to address both dermatological manifestations and frequently coexisting depressive symptoms through modulation of inflammatory signaling and tryptophan metabolism 41524454Jan. A sophisticated combination therapy approach for inflammatory skin diseases (psoriasis and atopic dermatitis) employed a pH-responsive hydrogel system co-delivering the JAK1 inhibitor upadacitinib with CCR7-targeting siRNA, which synergistically suppressed JAK-STAT and PI3K/AKT/mTOR pathway signaling, reduced pro-inflammatory cytokines, restored barrier function, and ameliorated lesions in disease models 42237357Jun. TYK2 inhibition has also been evaluated in systemic lupus erythematosus, where deucravacitinib, a selective TYK2 inhibitor, was studied in the phase 2 PAISLEY SLE trial with mechanistic insights derived from whole blood transcriptome profiling 42115051May.

Beyond inflammatory diseases, TYK2-JAK1 targeting has revealed broader therapeutic potential. In regenerative medicine, ruxolitinib conditioning of hESC-derived retinal pigment epithelium transplants attenuates IFN-γ-JAK1 signaling-driven immunogenicity, reducing T/NK-cell infiltration and improving graft survival and visual function in humanized retinal degeneration models without requiring chronic systemic immunosuppression 42309064Jun. In cancer, filgotinib, a selective JAK1 inhibitor approved for inflammatory diseases, induces apoptosis in colorectal cancer cells through p53 signaling pathway activation, revealing previously unexplored anti-tumor effects 42364020Jun. For myelofibrosis with splenomegaly and moderate-to-severe anemia, momelotinib, a JAK1/JAK2/ACVR1 inhibitor approved for the disease, has shown clinical benefit in real-world settings after ruxolitinib failure 42118670May.

Novel protein degradation platforms are expanding the TYK2-JAK1 therapeutic toolkit. RIMTAC (RIPK1-Mediated Targeting Chimeras) represents an innovative approach to targeted protein degradation that indirectly recruits VHL through hijacking the endogenous RIPK1-VHL complex, with JAK1 among the initial proof-of-concept targets, demonstrating potent, concentration- and time-dependent degradation through a ubiquitin-proteasome system-dependent mechanism that requires a quaternary complex of VHL, RIPK1, the target protein, and the RIMTAC molecule 42417401Jul.

What Changes, What Holds

1. TYK2-JAK1 now looks like a broader disease-modifying axis than an inflammation-only target
NEW DIRECTION Recent work extends the baseline’s inflammatory framing into dermatomyositis, psoriasis-associated mood symptoms, and systemic lupus, suggesting the TYK2-JAK1 axis may influence both immune pathology and linked neuroimmune/metabolic features 41910335Mar41524454Jan42115051May. That broadens the therapeutic rationale beyond cytokine suppression alone, but it does not displace the established view that the axis is chiefly relevant to immune dysregulation. The main uncertainty is whether these added roles are generalizable or disease-specific.

2. JAK1 inhibition is being repurposed into regenerative, oncologic, and post-ruxolitinib settings
NEW DIRECTION Work in retinal transplantation, colorectal cancer, and myelofibrosis pushes JAK1-targeting beyond the baseline’s inflammatory disease focus, showing that the same signaling node can be exploited to reduce graft immunogenicity, trigger tumor-cell death, or provide salvage benefit after prior JAK inhibition 42309064Jun42364020Jun42118670May. This expands the entity’s practical scope, but the evidence is heterogeneous and does not yet establish a unified noninflammatory indication.

3. Targeted degradation may become a new way to manipulate JAK1 biology
METHOD The degradation-platform study changes how JAK1 is approached experimentally, introducing a mechanism for induced protein removal rather than conventional catalytic inhibition 42417401Jul. That is a methodological expansion, not a revision of the baseline’s account of TYK2-JAK1 as a signaling target. Its significance is that it may enable more complete pathway suppression and new probe design, but the work is still proof-of-concept and does not yet redefine clinical use.

Overview update candidates: TYK2-JAK1’s scope may merit expansion to include neuroimmune/metabolic effects in psoriasis; lupus mechanistic profiling; regenerative immunomodulation; and targeted protein degradation as an enabling platform.